Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case Study
To fully capture the potential savings of biosimilars, governments should take measures to increase their uptake. The Belgian government, and also the manufacturers of biosimilars, should take measures to reduce the uncertainties related to biosimilars and raise confidence among prescribers. In addition, the financing of hospitals should be reformed and incentives should be developed to stimulate physicians to prescribe biosimilars. </AbstractSection> Copyright Springer International Publishing Switzerland 2014
Year of publication: |
2014
|
---|---|
Authors: | Dylst, Pieter ; Vulto, Arnold ; Simoens, Steven |
Published in: |
PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 32.2014, 7, p. 681-691
|
Publisher: |
Springer |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
Generic Medicines: Solutions for a Sustainable Drug Market?
Dylst, Pieter, (2013)
-
Dylst, Pieter, (2011)
-
Does the Market Share of Generic Medicines Influence the Price Level?
Dylst, Pieter, (2011)
- More ...